Rapport Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a) None.
(b) Not applicable.
(c) Trading Plan.
During the quarter ended September 30, 2026, the following officer (as defined in Rule 16a-1(f) under the Exchange Act) adopted a certain trading plan intended to satisfy the requirements of Rule 10b5-1(c):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Troy Ignelzi(Chief Financial Officer) | Adoption (September 4, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | Approximately 12 months | 72,000 |
During the quarter ended September 30, 2026, no other directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified, and/orterminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as such terms are defined in Item 408(a)of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.